IN VITRO AND IN VIVO MODELS & DRUG SCREENING
SALUVET-innova is a reference in the standardization of in vitro models and the development of animal models for diseases caused by protozoa parasites: neosporosis (Include links to publications), besnoitiosis (Include links to publications), toxoplasmosis (Include links to publications) and cryptosporidiosis (Include links to publications). All the models have been completely normalized and refined, determining variables that ensure their reproducibility: isolate, dose and route of inoculation where appropriate.
In vitro models are essential for screening and to determine the efficacy of existing drugs and identify new active compounds (Add link to the page of services and products). Animal models are the basis for the evaluation of drugs and vaccines against infection and clinical consequences (Add link to the page of services and products).
Currently, the SALUVET research group is evaluating the safety and efficacy of several new generation inhibitors of protein kinases (BKIs) in in vitro and in vivo models against Toxoplasma gondii, Neospora caninum and Besnoitia besnoiti infections. In addition, it has identified two drugs already marketed that are effective against infection by Besnoitia besnoiti in vitro, which could be suitable for treatment.
In vitro models are essential for screening and to determine the efficacy of existing drugs and identify new active compounds (Add link to the page of services and products). Animal models are the basis for the evaluation of drugs and vaccines against infection and clinical consequences (Add link to the page of services and products).
Currently, the SALUVET research group is evaluating the safety and efficacy of several new generation inhibitors of protein kinases (BKIs) in in vitro and in vivo models against Toxoplasma gondii, Neospora caninum and Besnoitia besnoiti infections. In addition, it has identified two drugs already marketed that are effective against infection by Besnoitia besnoiti in vitro, which could be suitable for treatment.
| besnoitiainvitro2.pdf |
